Selective replicating viral vectors: Potential for use in cancer gene therapy

BioDrugs

Volumn 17, Issue 4, 2003, Pages 251-262

  Nemunaitis, John ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; CELL SURFACE RECEPTOR; CISPLATIN; COMPLEMENTARY DNA; CV 706; CV 787; CYTOCHROME P450; FLUOROURACIL; G 207; GANCICLOVIR; HSV 1716; INTEGRIN; INTERLEUKIN 2; IRINOTECAN; KALLIKREIN; MESSENGER RNA; ONCOLYTIC VIRUS; ONYX 015; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; RETINOBLASTOMA PROTEIN; RETROVIRUS VECTOR; STRUCTURAL PROTEIN; THYMIDINE KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VIRUS DNA; VIRUS PROTEIN; VIRUS VECTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CELL CYCLE S PHASE; CELL DEATH; CELL SURFACE; CELL SURVIVAL; CHILL; CLINICAL TRIAL; DNA MODIFICATION; DNA REPLICATION; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; FEVER; GENE ACTIVATION; GENE CONSTRUCT; GENE CONTROL; GENE DELETION; GENE IDENTIFICATION; GENE INSERTION; GENE TARGETING; GENETIC ENGINEERING; HEAD AND NECK CANCER; HEMATURIA; HERPES SIMPLEX VIRUS; HUMAN; INJECTION PAIN; INTERNALIZATION; LIVER TOXICITY; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; RECEPTOR AFFINITY; REVIEW; SQUAMOUS CELL CARCINOMA; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS DNA CELL DNA INTERACTION; VIRUS GENE; VIRUS PARTICLE; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ANIMALS; DNA VIRUSES; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEOPLASMS; SIMPLEXVIRUS; VACCINIA VIRUS; VIRUS REPLICATION;

EID: 0043235645     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200317040-00004     Document Type: Review

References (217)

1. Hansen RM, Libnoch JA. Remission of chronic lymphocytic leukemia after smallpox vaccination. Arch Intern Med 1978; 138: 1137-8
2. Bousser J, Zittoun R. Prolonged spontaneous remission of chronic lymphoid leukemia. Nouv Rev Fr Hematol 1965; 5:498-501
3. Vladimirskaia EB. A case of prolonged spontaneous remission in a patient with chronic lymphocytic leukemia. Probl Gematol Pereliv Krovi 1962; 7:51-4
4. Weintraub LR. Lymphosarcoma: remission associated with viral hepatitis. JAMA 1969; 24: 1590-1
5. Sinkovics JG. Oncolytic viruses and viral oncolysates. Ann Immunol Hung 1986; 26: 271-90
6. Dock G. Influence of complicating diseases upon leukemia. Am J Med Sci 1904; 127: 563-92
7. Bierman HR, Hammon WM, Eddie BU, et al. The effect of viruses and bacterial infections on neoplastic diseases [abstract]. Cancer Res 1950; 10: 203-4
8. Bluming AZ, Ziegler JL. Regression of Burkitt's lymphoma in association with measles infection. Lancet 1971; 2 (7715): 105-6
9. Taqi AM, Abdurraham MB, Yabubu AM, et al. Regression of Hodgkin's disease after measles [abstract]. Lancet 1981; I (8229): 1112
10. Hernandez A. Observacion de un case de enfermedad de Hodgkin, con regresion de los sintomas e infartos ganglionares, post-sarampion. Rev Med Cubana 1949; 60: 120-5
11. Bierman HR, Crile DM, Dod KS. Remissions in leukemia of childhood following acute infectious disease: staphylococcus and streptococcus, varicella, and feline panleukopenia. Cancer 1953; 6: 591-605
12. Pelner L, Fowler GA, Nauts HC. Effects of concurrent infections and their toxins on the course of leukemia. Acta Med Scand 1958; 338 Suppl.: 1-47
13. London RE. Multiple myeloma: report of a case showing unusual remission lasting two years following severe hepatitis. Ann Intern Med 1955; 43: 191-201
14. De Pace NG. Case report: cervical cancer regression following rabies vaccination. Ginnecologia 1912; 9: 82
15. Pack GT. Note of the experimental use of rabies vaccine for melanomatosis. Arch Dermatol Syphilol 1950; 62: 694-5
16. Southam CM. Present status of oncolytic virus studies. Trans N Y Acad Sci 1960; 22: 657-73
17. Asada T. Treatment of human cancer with mumps virus. Cancer 1974; 34 (16): 1907-28
18. Yamanishi E, Takahashi M, Kurimura T, et al. Studies on live mumps virus vaccine: III. Evaluation of newly developed live mumps virus vaccine. Biken J 1970; 13: 157-61
19. Moore AE. Carcinolytic viruses. In: Harris RJC, editor. Biological approaches to cancer chemotherapy. New York: Academic Press, 1961: 365-70
20. Sinkovics JG. In: Die grundlagen der virusforschung. Budapest: Ungarische Akademie der Wissenschaften, 1956: 98-103, 235-47
21. Harris JE, Sinkovics JG, editors. The immunology of malignant disease. St Louis: Mosby, 1976: 180-2, 464-7, 475-8
22. Hoster HA, Zanes RP, von Haam E. Studies in Hodgkin's syndrome. Cancer Res 1949; 9: 473-80
23. Nemunaitis J. Oncolytic viruses. Invest New Drugs 1999; 17: 375-86
24. Seidman MA, Hogan SM, Wendland RL, et al. Variation in adenovirus receptor expression and adenovirus vector-mediated transgene expression at defined stages of the cell cycle. Mol Ther 2001; 4: 13-21
25. Kruyt FAE, Curiel DT. Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum Gene Ther 2002; 13: 485-95
26. Ramachandra M, Rahman A, Zou A, et al. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nature 2001; 19: 1035-41
27. Bai M, Harfe B, Freimuth P. Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells. J Virol 1993; 67: 5198-205
28. Wickham TJ, Mathias P, Cheresh DA, et al. Integrins avB3 and avB5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-19
29. Huang S, Kamata T, Takada Y, et al. Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. J Virol 1996; 70: 4502-8
30. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-3
31. Bergelson JM. Receptors mediating adenovirus attachment and internalization. Biochem Pharmacol 1999; 57: 975-9
32. Tomko RP, Xu R, Philipson L. HCAR and MCAR the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci U S A 1997; 94: 3352-6
33. Davison E, Diaz RM, Hart IR, et al. Integrin a5B1-mediated adenovirus infection is enhanced by the integrin-activating antibody TS2/16. J Virol 1997; 71: 6204-7
34. FitzGerald DJ, Padmanabhan R, Pastan I, et al. Adenovirus-induced release of epidermal growth factor and pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis. Cell 1983; 32: 607-17
35. 51Cr from KB cells at an acidic pH. J Biol Chem 1984; 259: 14350-3
36. Greber UF, Webster P, Weber J. et al. The role of the adenovirus protease on virus entry into cells. EMBO J 1996; 15: 1766-77
37. Greber UF, Suomalainen M, Stidwill RP, et al. The role of the nuclear pore complex in adenovirus DNA entry. EMBO J 1997; 16: 5998-6007
38. Leopold PL, Ferris B, Grinberg I, et al. Fluorescent visions: dynamic tracking of the pathway of adenoviral gene transfer vectors in living cells. Hum Gene Ther 1998; 9: 367-78
39. Wang K, Huang S, Kapoor-Munshi A, et al. Adenovirus internalization and infection require dynamin. J Virol 1998; 72: 3455-8
40. Suomalainen M, Nakano MY, Keller S, et al. Microtubule-dependent plus- and minus end-directed motilities are competing processes for nuclear targeting of adenovirus. J Cell Biol 1999; 144: 657-72
41. Wisnivesky JP, Leopold P, Crystal RG. Specific binding of the adenovirus capsid to the nuclear envelope. Hum Gene Ther 1999; 10: 2187-95
42. Leopold PL, Kreitzer G, Miyazawa N, et al. Dynein-microtubule-mediated translocation of adenovirus serotype 5 occurs after endosomal lysis. Hum Gene Ther 2000; 11: 151-65
43. Saphire AC, Guan T, Schirmer EC, et al. Nuclear import of adenovirus DNA in vitro involves the nuclear protein import pathway and hsp 70. J Biol Chem 2000; 275: 4298-304
44. Wold WSM, Doronin K, Toth K, et al. Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Curr Opin Immunol 1999; 11: 380-6
45. Mahr JA, Gooding LR. Immune evasion by adenoviruses. Immunol Rev 1999; 168: 121-30
46. Flint J, Shenk T. Viral transactivating proteins. Annu Rev Genet 1997; 31: 177-212
47. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274 (5286): 373-6
48. Rancourt C, Piche A, Gomez-Navarro J, et al. Interleukin-6 modulated conditionally replicative adenovirus as an antitumor cytotoxic agent for cancer therapy. Clin Cancer Res 1999; 5: 43-50
49. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the RB pathway produces anti-glioma effect in vivo. Oncogene 2000; 19: 2-12
50. Doronin K, Toth K, Kuppuswamy M, et al. Tumor-specific, replication-competent adenovirus vectors over expressing the adenovirus death protein. J Virol 2000; 74: 6147-55
51. Howe J, Demers GW, Johnson DE, et al. Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy. Mol Ther 2000; 2: 485-95
52. Heise C, Hermiston T, Johnson L, et al. An adenovirus E1-A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000; 6: 1134-9
53. Kratzer F, Rosorius O, Hieger P, et al. The adenovirus type 5 EIB-55K oncoprotein is a highly active shuttle protein and shuttling is independent of E4orf6, p53 and Mdm2. Oncogene 2000; 19: 850-7
54. Harada J, Berk A. p53-independent and -dependent requirements for E1B-55kD in adenovirus type 5 replication. J Virol 1999; 73: 5333-44
55. Braithwaite AW, Russel IA. Induction of cell death by adenovirus. Apoptosis 2001; 6: 359-70
56. Tollefson AE, Scaria A, Hermiston TW, et al. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 1996; 70 (4): 2296-306
57. Hawkins LK, Hermiston TW. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the ADP region. Gene Ther 2001; 8: 1131-41
58. Curiel DT. The development of conditionally replicative adenoviruses for cancer therapy. Clin Cancer Res 2000; 6: 3395-9
59. Gomez-Navarro J, Curiel DT. Conditionally replicative adenoviral vectors for cancer gene therapy. Lancet Oncol 2000; 1: 148-58
60. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001; 7: 781-7
61. Rodriguez R, Schuur ER, Lim HY, et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57: 2559-63
62. Alemany R, Lai S, Lou Y-C, et al. Complementary adenoviral vectors for oncolysis. Cancer Gene Ther 1999; 6: 21-5
63. Jordan MA, Toso RJ, Thrower D, et al. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A 1993; 90: 9552-6
64. Long BH, Fairchild CR. Paclitacel inhibits progression of mitotic cells to GI phase by interference with spindle formation without affecting other microtubule functions anaphase and telephase. Cancer Res 1994; 54: 4355-61
65. Adams JD, Flora KP, Goldspiel BR, et al. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monogr 1993; (15): 141-7
66. Kohn KW, Jackman J, O'Connor PM. Cell cycle control and cancer chemotherapy. J Cell Biochem 1994; 54: 440-52
67. Edelman MJ, Candra DR. Promising new agents in the treatment of non-small cell lung cancer. Cancer Chemother Pharmacol 1996; 37: 385-93
68. Ikeda K, Ichikawa T, Wakimoto H, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999; 5: 881-7
69. Wold WS, Hermiston TW, Tollefson AE. Adenovirus proteins that subvent host defenses. Trends Microbiol 1994; 2: 437-43
70. Wold WS, Tollefson AE, Hermiston TW. E3 transcription unit of adenovirus. Curr Top Microbiol Immunol 1995; 199: 237-74
71. Horwitz MS, Tufariello J, Grunhaus A. Model system for studying the effects of adenovirus E3 gene on virulence in vivo. Curr Top Microbiol Immunol 1995; 199: 195-211
72. Lee MG, Abina MA, Haddada H, et al. The constitutive expression of the immunomodulatory gp 19k protein in E1-, E3-adenoviral vectors strongly reduces the host cytotoxic T-cell response against the vector. Gene Ther 1995; 2: 256-62
73. Bett AJ, Haddara W, Prevec L, et al. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci U S A 1994; 91: 8802-6
74. Lian Y. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc Natl Acad Sci U S A 1997; 94: 2587-92
75. Elkon KB. Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors. Immunology 1997; 94: 9814-9
76. Benihoud K. Efficient, repeated adenovirus-mediated gene transfer in mice lacking both tumor necrosis factor alpha and lymphotoxin alpha. J Virol 1998; 72: 9514-25
77. Alcami A, Koszinowski UH. Viral mechanisms of immune evasion. Immunol Today 2000; 21: 447-55
78. Nash P, Barret JX, Cao S, et al. Immunomodulation by viruses: the myxoma virus story. Immunol Rev 1999; 168: 103-20
79. Smith GL, Symons JA, Khanna A, et al. Vaccinia virus immune evasion. Immunol Rev 1997; 159: 137-54
80. Smith VP, Bryant NA, Alcami A. Ectromelia, vaccinia and cowpox viruses encode secreted interleukin-18-binding proteins. J Gen Virol 2000; 81: 1223-30
81. Spriggs M. One step ahead of the game: viral immunomodulatory molecules. Annu Rev Immunol 1996; 14: 101-30
82. Saraiva M, Alcami A, CrmE, a novel soluble tumor necrosis factor receptor encoded by poxviruses. J Virol 2001; 75 (1): 226-33
83. Rahman A, Tsai V, Goudreau A, et al. Specific depletion of human anti-adenovirus antibodies facilitates transduction in an in vivo model for systematic gene therapy. Mol Ther 2001; 3 (5 Pt 1): 768-78
84. Lorence RM, Roberts MS, Groene WS, et al. Replication-competent, oncolytic Newcastle disease virus for cancer therapy. In: Driever PH, Roabkin SD, editors. Replication-competent viruses for cancer therapy: monographs in virology. Vol. 22. Basel: Karger, 2001: 160-82
85. Li E, Stupack D, Bokoch GM, et al. Adenovirus endocytosis requires actin cytoskeleton organization mediated by Rho family GTPases. J Virol 1998; 72: 8806-12
86. Wolff G, Worgall S, van Rooijen N, et al. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol 1997; 71: 624-9
87. Biewenga J, van der Ende MB, Krist LF, et al. Macrophage depletion in the rat after intraperitoneal administration of liposome-encapsulated clodronate: depletion kinetics and accelerated repopulation of peritoneal and omental macrophages by administration of Freund's adjuvant. Cell Tissue Res 1995; 280: 189-96
88. McCuskey RS, McCuskey PA, Urbaschek R, et al. Kupffer cell function in host defense. Rev Infect Dis 1999; 9: 616-9
89. Huitinga L, Ruuls SR, Jung S, et al. Macrophages in T cell line-mediated demyelinating and chronic relapsing experimental autoimmune encephalomyelitis in Lewis rats. Clin Exp Immunol 1995; 10: 344-51
90. Laman JD, Kors N, van Rooijen N, et al. Mechanism of follicular trapping localization of immune complexes and cell remnants after elimination and repopulation of different spleen cell populations. Immunology 1990; 71: 57-62
91. Pinto AJ, Stewart D, van Rooijen N, et al. Selective depletion of liver and splenic macrophages using lyposomes encapsulating the drug dichloromethylene diphosphonate: effects of antimicrobial resistance. J Leukoc Biol 1991; 49: 579-86
92. Qiam Q, Jutila A, van Rooijen N, et al. Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidates. J Immunol 1994; 152: 5000-8
93. Tscaikowsky D, Brain JD. Effects of liposome-encapsulated dichloromethylene diphosphonate on macrophage function and endotoxin-induced mortality. Biochim Biophys Acta 1994; 3: 323-30
94. Van Rooijen N. The liposome-mediated macrophage 'suicide' technique. J Immunol Methods 1989; 124: 1-6
95. Van Rooijen N, Kors N, Kraal G. Macrophage subset repopulation in the spleen differential kinetics after liposome-mediated elimination. J Leukoc Biol 1989; 45: 97-104
96. Van Rooijen N, Kors N, van der Ende MB, et al. Depletion and repopulation of macrophages in spleen and liver of rat after intravenous treatment with liposome-encapsulated dichloromethylene diphosphonate. Cell Tissue Res 1990; 260: 215-22
97. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages mechanism of action preparation of liposomes and application. J Immunol Methods 1994; 174: 83-93
98. Van Rooijen N, Sanders A. Kupffer cell depletion by liposome-delivered drugs: comparative activity of intracellular clodronate propamidine and ethylene-diaminetetraacetic acid. Hepatology 1996; 23: 1239-43
99. Vreden SG. Kupffer cell elimination enhances development of liver schizonts of Plasmodium berghei in rats. Infect Immun 1993; 61: 1936-9
100. Lechner MS, Mack DH, Finicle AB, et al. Human papilloma virus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J 1992; 11: 3045-52
101. Gannon JV, Lane DP. p53 and DNA polymerase alpha compete for binding to SV40 T antigen. Nature 1987; 329: 456-8
102. Goodrum FD, Ornelles DA. The early region 1B 55-kilodalton oncoprotein of adenovirus relieved growth restrictions imposed on viral replication by the cell cycle. J Virol 1997; 71: 548-61
103. Hall AR, Dix BR, O'Carroll SJ, et al. p-53 dependent cell death/ apoptosis is required for a productive adenovirus infection. Nat Med 1998; 4: 1068-72
104. Turnell AS, Grand RJ, Gallimore PH. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status. J Virol 1999; 73: 2074-83
105. Goodrum FD, Ornelles DA. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lyric injection. J Virol 1998; 72: 9479-90
106. Heise C, Sampson-Johannes A, Williams A, et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3 (6): 639-45
107. Kirn D, Hermiston T, McCormick LF. ONYX-015: clinical data are encouraging. Nat Med 1998; 4 (12): 1341-2
108. Rothmann T, Hengstermann A, Whitaker NJ, et al. Replication of ONYX-015, a potential anticancer adenovirus, is dependent of p53 status in tumor cells. J Virol 1998; 72: 9470-8
109. Yu DC, Sakamoto GT, Henderson DR. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res 1999; 59: 1498-504
110. Habib NA, Mitry RR, Sarraf CE, et al. Assessment of growth inhibition and morphological changes in in vitro and in vivo hepatocellular carcinoma models post treatment with d11520 adenovirus. Cancer Gene Ther 2002; 9: 414-20
111. Kenney S, Pagano JS. Viruses as oncolytic agents: a new age for 'therapeutic' viruses? J Natl Cancer Inst 1994; 86: 1185-6
112. Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A 1994; 91 (10): 4407-11
113. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 2000; 60: 6359-66
114. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001; 19: 289-98
115. Habib N, Salama H, Abd El Latif Abu Median A, et al. Clinical trial E1B-deleted adenovirus (d11520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther 2002; 9: 254-9
116. Khuri F, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-FU in patients with recurrent head and neck cancer. Nat Med 2000; 6 (8): 879-85
117. Nemunaitis J, Cunningham C, Tong AW, et al. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther 2003; 10 (5): 341-52
118. Vasey PA, Shulman LN, Campos S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (d11520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002; 20 (6): 1562-9
119. Ganly I, Kirn D, Eckhardt G, et al. A phase I study of ONYX-015, and E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000; 6: 798-806
120. Reid T, Galanis E, Abbruzzese J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (d11520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002; 62 (21): 6070-9
121. Mulvihill S, Warren R, Venook A, et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 2001; 8: 308-15
122. Nemunaitis J, Cunningham C, Buchanan A, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 2001; 8 (10): 746-59
123. Kirn D. Clinical research results with d11520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 2001 Jan; 8 (2): 89-98
124. Bayley ST, Mymryk JS. Adenovirus E1A proteins and transformation. Int J Oncol 1994; 5: 425-44
125. Howe JA, Bayley ST. Effects of Ad5E1A mutant viruses on the cell cycle in relation to the binding of cellular proteins including the retinoblastoma protein and cyclin A. Virology 1992; 186: 15-24
126. Howe JA, Mymryk JS, Egan C, et al. Retinoblastoma growth suppressor and a 300-kDa protein appear to regulate cellular DNA synthesis. Proc Natl Acad Sci U S A 1990; 87: 5883-7
127. Wang HG, Draetta G, Moran E. E1A induces phosporylation of the retinoblastoma protein independently of direct physical association between the E1A and retinoblastoma products. Mol Cell Biol 1991; 11: 4253-65
128. Dyson N, Buchkovich K, Whyte P, et al. Cellular proteins that are targeted by DNA tumor viruses for transformation. Princess Takamatsu Symp 1989; 20: 191-8
129. Moran E. DNA tumor virus transforming proteins and the cell cycle. Curr Opin Genet Dev 1993; 3: 63-70
130. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-3330
131. Dubensky Jr TW. (Re-) engineering tumor cell-selective replicating adenoviruses: a step in the right direction toward systematic therapy for metastatic disease. Cancer Cell 2002; 1: 307-8
132. Johnson L, Shen A, Boyle L, et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systematic antitumor agents. Cancer Cell 2002; 1: 325-37
133. Tsukuda K, Wiewrodt R, Molnar-Kimber K, et al. An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. Cancer Res 2002 Jun 15; 62 (12): 3438-47
134. Wildner O, Morris JC, VanHanian NN, et al. Adenoviral vectors capable of replication improve the efficacy of HSYtk/GCV suicide gene therapy of cancer. Gene Ther 1999; 6: 57-62
135. Kurihara T, Brough DE, Kovesdi I, et al. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUCI antigen. J Clin Invest 2000; 106: 763-71
136. Geoerger B, Grill J, Opolon P, et al. ONYX-015, an E1B-55kD deleted adenovirus, potentiates radiation therapy in human malignant glioma xenografts [abstract no. 209]. Proc Am Soc Clin Oncol 2001; 20: 53a
137. Lamfers MLM, Grill J, Dirven CM, et al. Potential of the conditionally replicative adenovirus Ad5-24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 2002; 62: 5736-42
138. Van Beusechem VW, van den Doel PB, Grill J, et al. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res 2002; 62: 6165-71
139. Nemunaitis J, Senzer N, Cunningham C, et al. Virus-mediated killing of cells that lack p53 activity. Drug Resist Updat 2001 Oct; 4 (5): 289-91
140. DeWeese TL, van der Poel H, Li A, et al. A phase 1 trial of CV706, a replication-competent, PSA selective oncolytic adenovirus for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001; 61: 7464-72
141. Chen Y, De Weese T, Dilley J, et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res 2001; 61: 5453-60
142. Garzotto M, Haimovitz-Friedman A, Liao W-C, et al. Reversal radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase. Cancer Res 1999; 59: 5194-201
143. Chen Y, Yu DC, Charlton D, et al. Pre-existent adenovirus antibody inhibits systematic toxicity and antitumor activity of Cn706 in the nude mouse LNCaP xenografi model: implications and proposals for human therapy. Human Gene Ther 2000; 11: 1553-67
144. Yu DC, Chen Y, Seng M, et al. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 1999; 59: 4200-3
145. Yu DC, Chen Y, Dilley J, et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001; 61: 517-25
146. Li Y, Yu DC, Chen Y, et al. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res 2001; 61: 6428-36
147. Vile RG, Hart IR. In vitro targeting of gene expression to melanoma cells. Cancer Res 1993; 53: 962-7
148. Morelli AE, Larregina AT, Smith-Arica J, et al. Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity. J Gen Virol 1999; 80: 571-83
149. Gao Z, Fields JZ, Boman BM, Tumor-specific expression of anti-mdr1 ribozyme selectively restores chemosensitivity in multidrug resistant colon-adenocarcinoma cells. Intl J Cancer 1999; 82: 346-52
150. Deweese T, Drew R, Li S. et al. Final results of a phase I study of CV706, a conditionally replication-competent cytolytic adenovirus, for the treatment of locally-recurrent prostate cancer [abstract]. Mol Ther 2001; 3: S310
151. Hallenbeck PL, Chang YN, Hay C. et al. A novel tumor specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999; 10: 1721-33
152. Hernandez-Alcoceba R, Pihalja M, Wicha MS, et al. A novel, conditionally replicative adenovirus of the treatment of breast cancer that allows controlled replication of E1A-deleted adenoviral vectors. Hum Gene Ther 2000; 11: 2009-24
153. Lee F, Mulligan R, Berg P, et al. Glucocorticosteroids regulate expression of dihydrofolate reductase cDNA in mouse mammary tumor virus chimeric plasmids. Nature 1981; 294: 228-32
154. Steele C, Sacks PG, Adler-Storthz K, et al. Effects on cancer cells of plasmids that express antisense RNA of human papilloma virus type 18. Cancer Res 1992; 52: 4706-11
155. Gibson SA, Pellenz C, Hutchison RE, et al. Induction of apoptosis in oral cancer cells by an anti-bcl-2 ribozyme delivered by an adenovirus vector. Clin Cancer Res 2000 Jan; 6 (1): 213-22
156. Lee G, Hung HJ, You YO, et al. Effect of p53 gene transfer on the cell proliferation and cell line with p53 mutations. Intl J Oral Biol 1998; 23: 189-99
157. Walther W, Wendt J, Stein U. Employment of the mdr1 promoter for the chemotherapy-inducible expression of therapeutic genes in cancer gene therapy. Gene Ther 1997; 4: 544-52
158. Nguyen KT, Liu B, Ueda K, et al. Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants. Oncol Res 1994; 6: 71-7
159. Thompson EM, Nagata S, Tsuji FI. Vargula hilgendorfii luciferase: as secreted reporter enzyme for monitoring gene expression in mammalian cells. Gene 1990; 96: 257-62
160. Kawakami K, Kawakami M, Joshi BH, et al. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res 2001; 61: 6194-200
161. Shillitoe EF, Noonan S. Strength and specificity of different gene promoters in oral cancer cells. Oral Oncol 2000; 36: 214-20
162. Park JO, Lopez CA, Gupta VK, et al. Transcriptional control of viral gene therapy by cisplatin. J Clin Invest 2002; 110 (3): 403-10
163. Hallahan DE, Mauceri HJ, Seung LP, et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1995; 1: 786-91
164. Avvakumov N, Mymryk JS. New tools for the construction of replication-competent adenoviral vectors with altered E1A regulation. J Virol Methods 2002 May; 103 (1): 41-9
165. Chong H, Ruchatz A, Clackson T, et al. A system for small-molecule control of conditionally replication-competent adenoviral vectors. Mol Ther 2002 Feb; 5 (2): 195-203
166. Savontaus MJ, Sauter BV, Huang TG, et al. Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells. Gene Ther 2002 Jul; 9 (14): 972-9
167. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 1994; 54: 3963-6
168. Chase M, Chung RY, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgenes and augments cyclophosphamide chemotherapy. Nat Biotechnol 1998; 16: 444-8
169. Boviatsis EJ, Scharf JM, Chase M, et al. Antitumor activity and reporter gene transfer into rat brain or ribonucleotide reductase. Gene Ther 1994; 1 (5): 323-31
170. Chou J, Kein E, Whitley RJ, et al. Mapping of herpes simplex virus-1 neurovirulence to gamma, 34.5, a gene nonessential for growth in culture. Science 1990; 250: 1262-6
171. Chou J, Roizman B. The gamma 1 (34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells. Proc Natl Acad Sci U S A 1992; 89: 3266-70
172. McKie EA, Maclean AR, Lewis AD, et al. Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumors: evaluation of a potentially effective clinical therapy. Br J Cancer 1996; 74: 745-52
173. Martuza RL. Act locally, think globally [letter]. Nat Med 1997; 3: 1323
174. Alemany R, Gomez-Manzano C, Balague C, et al. Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res 1999; 252: 1-12
175. Pennisi E. Will a twist of viral fate lead to a new cancer treatment? Science 1996; 274: 342-3
176. Mineta T, Rabkin SD, Yazaki T, et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938-43
177. Chambers R, Gillespe GY, Soroceanu L, et al. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in SCID mouse model of human malignant glioma. Proc Natl Acad Sci U S A 1995; 92: 1411-5
178. Kesari S, Randazzo BP, Valyi-Nagy T, et al. Therapy of experimental human brain tumors using a neuro attenuated herpes simplex virus mutant. Lab Invest 1995; 73: 636-48
179. Andreansky SS, He B, Gillespe GY, et al. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci U S A 1996; 93: 11313-8
180. Kucharzuk JC, Randazzo B, Elshami AA, et al. Use of a replication-restricted recombinant herpes virus to treat localized human malignancy. Cancer Res 1997; 57: 466-71
181. Toyozuimi T, Mick R, Abbas AE, et al. Combined therapy with chemotherapeutic agents and herpes simplex virus type-1 ICP34.5 mutant (HSC-1716) in human non-small lung cancer. Hum Gene Ther 1999; 10: 3013-29
182. Advani SJ, Chung SM, Yan SY, et al. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res 1999; 59: 2055-8
183. Carroll NM, Chiocca EA, Takahashi K, et al. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg 1996; 224: 323-9
184. Lambright E, Kang EH, Force S, et al. Effect of pre-existing anti-herpes immunity on the efficacy of herpes simplex virus therapy in a murine intraperitoneal tumor model. Mol Ther 2000; 2: 387-93
185. Randazzo BP, Bhat MG, Kesari S, et al. Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. J Invest Dermatol 1997; 108: 933-7
186. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication competent multimutated herpes simplex virus 1. Hum Gene Ther 1998; 9: 2177-85
187. Toda M, Rabkin AD, Kojima H, et al. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 1999; 10: 385-93
188. Yoon SS, Carroll NM, Chiocca EA, et al. Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. Ann Surg 1998; 228: 366-74
189. Coukus G, Makrigiannakis A, Kang EH, et al. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res 1999; 5: 1523-37
190. Coukus G, Rubin SC, Molanr-Kimber KL. Application for recombinant herpes simplex virus-1 (HSV-1) for the treatment of malignancies outside the central nervous system. Gene Ther Mol Biol 1999; 3: 79-89
191. Lambright ES, Caparrelli D, Abbas A, et al. Oncolytic therapy using a mutant type 1 herpes simplex virus and the role of the immune response. Ann Thorac Surg 1999; 68: 1756-62
192. Wong RJ, Kim SH, Joe JK, et al. Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg 2001 Jul; 193 (1): 12-21
193. Papanastassiou V, Rampling R, Frase M, et al. The potential for efficacy of the modified (ICP 34.5) herpes simplex virus HSV1716 following intratumoral injection into human malignant glioma: a proof of principle study. Gene Ther 2002; 9: 398-406
194. Jorgensen TJ, Katz S, Wittmack EK, et al. Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia 2001; 3: 451-6
195. Spear MA, Sun F, Eling DJ, et al. Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide-reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. Cancer Gene Ther 2000; 7: 1051-9
196. Advani SJ, Sibley GS, Song PY, et al. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gen Ther 1998; 5: 160-5
197. Bradley JD, Kataoka Y, Advani S, et al. Ionizing radiation improves survival in mice bearing intracranial high grade gliomas injected with genetically modified herpes simplex virus. Clin Cancer Res 1999; 5: 1517-22
198. Blank SV, Rubin SC, Coukus G, et al. Replication selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation. Hum Gene Ther 2002; 13: 627-39
199. Coukos G, Makrigiannakis A, Kang E, et al. ICP34.5 deficient herpes simplex virus-1 kills ovarian cancer cells via non-apoptotic or p53-independent apoptotic death: implications for chemotherapy-resistant disease. Clin Cancer Res 2000; 6: 3342-53
200. Endo T, Toda M, Watanabe M, et al. In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer. Cancer Gene Ther 2002; 9: 142-8
201. Toda M, Martuza RL, Koima H, et al. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol 1998; 160: 4457-64
202. Parker JN, Gillespie GY, Love CE, et al. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A 2000; 5: 2208-13
203. Andreansky S, He B, van Cott J, et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther 1998; 5 (1): 121-30
204. Pawlik TM, Nakamura H, Yoon SS, et al. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpes virus. Cancer Res 2000; 60: 2790-5
205. Mullen JT, Kasuya H, Yoon SS, et al. Regulation of herpes simplex virus 1 replication using tumor-associated promoters. Ann Surg 2002 Oct; 236 (4): 502-13
206. Khromykh AA. Replication-based vectors of positive strand RNA viruses. Curr Opin Mol Ther 2000; 2: 555-69
207. Andreu T, Ebensperger C, Westphal EM, et al. Self-deleting suicide vectors (SDSV): selective killing of p53-deficient cancer cells. Cancer Res 2001; 61 (18): 6925-30
208. Schutz A, Oertli D, Marti WR, et al. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen. Cancer Gene Ther 2001; 8 (9): 655-61
209. Tmiryasova TM, Chen B, Fodor I. Replication-deficient vaccinia virus gene therapy vector: evaluation of exogenous gene expression mediated by PUV-inactivated virus in glioma cells. J Gene Med 2001 Sep-Oct; 3 (5): 468-77
210. Gomella LG, Mastranelo MJ, McCue PA, et al. Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol 2001 Oct; 166 (4): 1291-5
211. Mastrangelo MJ, Maguire Jr HC, Eisiniohr LC, et al. Intratumoral recombinant GM-CSF-encoding virus to package amplicons containing cytokine gene therapy vector in cancer, persistent transgene expression despite antibody generation. Cancer Gene Ther 2000; 7: 663-70
212. Naik AM, Xu H, Alexander HR, et al. A mutant vaccinia virus with improved tumor selectivity. Proceedings of the 54th Annual SSO Cancer Symposium; 2001 Mar 15-18; Washington, DC
213. Hodge JW, Abrams S, Schlom J, et al. Induction of anti-tumor immunity by recombinant vaccinia virus expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 1994; 54: 5552-5
214. McCart JA, Puhlmann M, Lee J, et al. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther 2000; 7: 1217-23
215. Mukherjee S, Haenel T, Himbeck R, et al. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Ther 2000; 7 (5): 663-70
216. Pecora A, Rizvi N, Cohen GI, et al. Phase I trial of intravenous administration of PV701, an oncolytic vires, in patients with advanced solid cancers. J Clin Oncol 2002; 20 (9): 2251-66
217. Reid T, Galanis E, Abbruzzese J, et al. Intra-arterial administration of a replication-selective adenovirus (d11520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther 2001; 8 (21): 1618-26